# Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

> **NCT05266456** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vaxcyte, Inc.** · enrollment: 835 (actual)

## Conditions studied

- Pneumococcal Vaccines

## Interventions

- **BIOLOGICAL:** 24 valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 20 valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT05266456
- **Lead sponsor:** Vaxcyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-22
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 835 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266456, "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05266456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*